Ackman says Valeant regulatory compliance no worse than rest of pharma industry By: MarketWatch October 30, 2015 at 15:21 PM EDT Ackman may be setting the bar low for Valeant, based on how often drug companies pay fines for illegal activity. Read More >> Related Stocks: Abbott Laboratories Gsk Plc ADR Johnson & Johnson Merck & Co Novartis Ag ADR Pfizer Senvest Capital Inc Valeant Pharmaceuticals International, Inc.